TY - JOUR
T1 - Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of the original mRNA vaccine
AU - Xie, Xuping
AU - Zou, Jing
AU - Kurhade, Chaitanya
AU - Liu, Mingru
AU - Ren, Ping
AU - Pei-Yong Shi, Shi
N1 - Funding Information:
We thank colleagues at the University of Texas Medical Branch (UTMB) for helpful discussions. We thank Michael L O’Rourke from the Information System Department at UTMB for assisting with electronic medical record systems. P.-Y.S. was supported by NIH contract HHSN272201600013C and awards from the Sealy & Smith Foundation , the Kleberg Foundation , the John S. Dunn Foundation , The Amon G. Carter Foundation , the Summerfield Robert Foundation , and Edith and Robert Zinn .
Funding Information:
We thank colleagues at the University of Texas Medical Branch (UTMB) for helpful discussions. We thank Michael L O'Rourke from the Information System Department at UTMB for assisting with electronic medical record systems. P.-Y.S. was supported by NIH contract HHSN272201600013C and awards from the Sealy & Smith Foundation, the Kleberg Foundation, the John S. Dunn Foundation, The Amon G. Carter Foundation, the Summerfield Robert Foundation, and Edith and Robert Zinn. Conceptualization, X.X. P.R. and P.-Y.S.; methodology, X.X. J.Z. C.K. M.L. P.R. and P.-Y.S.; investigation, X.X. J.Z. C.K. M.L. P.R. and P.-Y.S.; resources, X.X. P.R. and P.-Y.S.; data curation, X.X. J.Z. C.K. M.L. and P.R.; writing – original draft, X.X. J.Z. R.R. and P.-Y.S.; writing – review & editing, X.X. P.R. and P.-Y.S.; supervision, X.X. P.R. and P.-Y.S.; funding acquisition, P.-Y.S. X.X. and P.-Y.S. have filed a patent on the reverse genetic system. X.X. J.Z. and P.-Y.S. received compensation from Pfizer for COVID-19 vaccine development.
Publisher Copyright:
© 2022 The Author(s)
PY - 2022/11/29
Y1 - 2022/11/29
N2 - Since the initial emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.1, several Omicron sublineages have emerged, leading to BA.5 as the current dominant sublineage. Here, we report the neutralization of different Omicron sublineages by human sera collected from individuals who had distinct mRNA vaccination and/or BA.1 infection. Four-dose-vaccine sera neutralize the original USA-WA1/2020, Omicron BA.1, BA.2, BA.2.12.1, BA.3, and BA.4/5 viruses with geometric mean titers (GMTs) of 1,554, 357, 236, 236, 165, and 95, respectively; two-dose-vaccine-plus-BA.1-infection sera exhibit GMTs of 2,114, 1,705, 730, 961, 813, and 274, respectively; and three-dose-vaccine-plus-BA.1-infection sera show GMTs of 2,962, 2,038, 983, 1,190, 1,019, and 297, respectively. Thus, the four-dose vaccine elicits the lowest neutralization against BA.5; the two-dose vaccine plus BA.1 infection elicits significantly higher GMTs against Omicron sublineages than the four-dose-vaccine; and the three-dose vaccine plus BA.1 infection elicits slightly higher GMTs (statistically insignificant) than the two-dose vaccine plus BA.1 infection. Finally, the BA.2.75 is more susceptible than BA.5 to four-dose-vaccine-elicited neutralization and three-dose-vaccine-plus-BA.1-infection-elicited neutralization.
AB - Since the initial emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.1, several Omicron sublineages have emerged, leading to BA.5 as the current dominant sublineage. Here, we report the neutralization of different Omicron sublineages by human sera collected from individuals who had distinct mRNA vaccination and/or BA.1 infection. Four-dose-vaccine sera neutralize the original USA-WA1/2020, Omicron BA.1, BA.2, BA.2.12.1, BA.3, and BA.4/5 viruses with geometric mean titers (GMTs) of 1,554, 357, 236, 236, 165, and 95, respectively; two-dose-vaccine-plus-BA.1-infection sera exhibit GMTs of 2,114, 1,705, 730, 961, 813, and 274, respectively; and three-dose-vaccine-plus-BA.1-infection sera show GMTs of 2,962, 2,038, 983, 1,190, 1,019, and 297, respectively. Thus, the four-dose vaccine elicits the lowest neutralization against BA.5; the two-dose vaccine plus BA.1 infection elicits significantly higher GMTs against Omicron sublineages than the four-dose-vaccine; and the three-dose vaccine plus BA.1 infection elicits slightly higher GMTs (statistically insignificant) than the two-dose vaccine plus BA.1 infection. Finally, the BA.2.75 is more susceptible than BA.5 to four-dose-vaccine-elicited neutralization and three-dose-vaccine-plus-BA.1-infection-elicited neutralization.
KW - CP: Immunology
KW - CP: Microbiology
KW - SARS-CoV-2
KW - breakthrough
KW - mRNA vaccine
KW - neutralization
KW - variants
UR - http://www.scopus.com/inward/record.url?scp=85142498904&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85142498904&partnerID=8YFLogxK
U2 - 10.1016/j.celrep.2022.111729
DO - 10.1016/j.celrep.2022.111729
M3 - Article
C2 - 36402138
AN - SCOPUS:85142498904
VL - 41
JO - Cell Reports
JF - Cell Reports
SN - 2211-1247
IS - 9
M1 - 111729
ER -